INTERLEUKIN GENETICS, INC.

135 Beaver Street

Waltham, Massachusetts 02452

April 12, 2016

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Michael Gershon

Re:	Interleukin Genetics, Inc.
	Post-Effective Amendment No. 3 to
	Registration Statement on Form S-1
	Filed March 23, 2016
	File No. 333-189749

Dear Mr. Gershon:

With respect to the above-referenced Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Interleukin Genetics, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Thursday, April 14, 2016 at 4:30 p.m., or as soon as practicable thereafter.

In connection with the foregoing request, the Company acknowledges the following:

· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Brian Keane of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 348-3093 with any comments or questions regarding the Registration Statement.

Very truly yours,

/s/ Stephen J. DiPalma

Stephen J. DiPalma

Interim Chief Financial Officer